Key result
Management of cancer-associated thrombosis requires a multidisciplinary approach and consideration of individual patient preferences to balance risks of recurrent thromboembolic events and bleeding.
Why the study?
Optimal duration, intensity, and type of anticoagulation in cancer patients remain an area of ongoing debate, particularly balancing risks of recurrent thromboembolism and bleeding during active malignancy.
Management of cancer-associated thrombosis requires a multidisciplinary approach and individualized treatment to balance thrombosis and bleeding risks.
Cancer-associated thrombosis (CAT) is a common clinical problem in the treatment of cancer patients posing some unique challenges. These include the need to balance between the risk of recurrent thromboembolic events and bleeding complications in the individual cancer patient. A frequently encountered dilemma is the need for long-term anticoagulation in the setting of active malignancy. Until now, optimal duration, intensity, and type of anticoagulation in cancer patients remain an area of ongoing debate. In this case-based review, we present several challenging clinical scenarios and provide guidance on management. For optimal treatment results, CAT generally requires a multidisciplinary approach including specialists for thrombosis and hemostasis as well as hematology and oncology. Individual patient preferences should always be taken into account, especially in clinical situations with weak treatment evidence.
No takes yet. Share an insight, caveat, or question.
Balaian et al. (2024) conducted a review in Cancer-associated thrombosis. Anticoagulation was evaluated. Management of cancer-associated thrombosis requires a multidisciplinary approach and consideration of individual patient preferences to balance risks of recurrent thromboembolic events and bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: